What You Should Know:
– CVS Health Clinical Trial Services and late clinical-stage cellular therapeutics company ProKidney Corp. today announced a collaboration to enroll patients with type 2 diabetes and chronic kidney disease into the proact 1 (REGEN-006) Phase 3 clinical trial of REACT®.
ProKidney’s lead product candidate, REACT® (REnal Autologous Cell Therapy), is a first-of-its-kind, patented, autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases potentially drive meaningful improvement in kidney function.
